Advertisement

Topics

Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma

2014-08-27 03:17:56 | BioPortfolio

Summary

The aim of the study is to assess the therapeutic activity and safety of the combination of Bendamustine and Rituximab in MALT lymphomas.

Primary endpoint:

- Event-free-survival (EFS) (failure or death from any cause) for all patients.

Secondary endpoints:

- Complete and partial remission rates for all patients

- Response duration (time to relapse or progression) for responder patients

- Progression-free-survival (PFS) (disease progression or death from lymphoma: for all patients

- Overall survival for all patients

- Acute and long-term toxicity

Study Design

Allocation: Non-Randomized, Control: Uncontrolled, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

MALT Lymphoma

Intervention

Rituximab and Bendamustine

Location

Hospital Central de Asturias
Oviedo
Asturias
Spain
33006

Status

Recruiting

Source

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:17:56-0400

Clinical Trials [2168 Associated Clinical Trials listed on BioPortfolio]

Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma

Aim of the study is to assess the therapeutic activity and safety of the combination of Chlorambucil and Rituximab in MALT lymphomas and to determine whether the addition of Rituximab to C...

Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma (NHL) Unresponsive to Rituximab or a Rituximab-Containing Regimen

The purpose of this study is to evaluate the safety and efficacy of ofatumumab and bendamustine combination therapy in patients with indolent B-cell NHL that did not respond to rituximab o...

Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.

In phase I: Establishing maximally tolerated dose of lenalidomide in combination with bendamustine and rituximab. In phase II: Evaluation of progression free survival with treatment with ...

Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma

The goal of this multi-center Phase II study is to add bortezomib to the highly active regimen of bendamustine and rituximab. In this study, bortezomib will be administered on a weekly sc...

A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed Diffuse Large B-Cell Lymphoma (NAVIGATE)

This randomized, open-label, multicenter study will evaluate the efficacy and sa fety of navitoclax in addition to bendamustine and rituximab in patients with re lapsed diffuse large B-cel...

PubMed Articles [1034 Associated PubMed Articles listed on BioPortfolio]

Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase 1b dose-finding study.

Venetoclax is a selective, potent inhibitor of the anti-apoptotic BCL-2 protein approved for treatment of chronic lymphocytic leukemia. We conducted a dose-finding study of venetoclax in combination w...

Rituximab, Bendamustine and Cytarabine (R-BAC) in patients with relapsed-refractory aggressive B-cell lymphoma.

Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.

We report follow-up results from the randomized, placebo-controlled, phase 3 HELIOS trial of ibrutinib+bendamustine and rituximab (BR) for previously treated chronic lymphocytic leukemia (CLL)/small l...

Successful retreatment with 3-week rituximab-bendamustine with high-dose dexamethasone in patients with relapsed/refractory mantle cell lymphoma.

Colorectal MALT lymphoma: a rare clinical entity.

 Data on colorectal lymphoma in general and on MALT (mucosa-associated-lymphoid tissue) lymphoma, in particular are, very rare. There are no existing recommendations from current guidelines for how ...

Medical and Biotech [MESH] Definitions

A nitrogen mustard compound that functions as an ALKYLATING ANTINEOPLASTIC AGENT and is used in the treatment of CHRONIC LYMPHOCYTIC LEUKEMIA and NON-HODGKIN'S LYMPHOMA.

A murine-derived monoclonal antibody and ANTINEOPLASTIC AGENT that binds specifically to the CD20 ANTIGEN and is used in the treatment of LEUKEMIA; LYMPHOMA and RHEUMATOID ARTHRITIS.

Extranodal lymphoma of lymphoid tissue associated with mucosa that is in contact with exogenous antigens. Many of the sites of these lymphomas, such as the stomach, salivary gland, and thyroid, are normally devoid of lymphoid tissue. They acquire mucosa-associated lymphoid tissue (MALT) type as a result of an immunologically mediated disorder.

A caspase-like cysteine endopeptidase that also exhibits ubiquitin ligase activity. It contains an N-terminal DEATH DOMAIN, two IMMUNOGLOBULIN-LIKE DOMAINS, and localizes to the perinuclear region of MONOCYTES, where it functions in activation of NF-KAPPA B; it also binds to and activates TRAF6. Chromosomal translocations involving the MALT1 and BIRC2 genes are associated with MALT LYMPHOMA, and mutations in the MALT1 gene are associated with Type 12 IMMUNODEFICIENCY SYNDROMES.

A leukemia/lymphoma found predominately in children and young adults and characterized LYMPHADENOPATHY and THYMUS GLAND involvement. It most frequently presents as a lymphoma, but a leukemic progression in the bone marrow is common.

More From BioPortfolio on "Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial